一種無毒的植物配方能抑制小鼠體內(nèi)的人前列腺腫瘤,，相關(guān)研究論文發(fā)表在The International Journal of Oncology雜志上。美國印第安納大學(xué)衛(wèi)研究所研究人員發(fā)現(xiàn)這一抑制前列腺的配方能顯著抑制腫瘤生長,，在侵襲性的激素抵抗性（雄激素非依賴性）人前列腺癌細(xì)胞,。這項研究還表明該配方即使在高劑量情況下也沒有毒副作用。
研究員和配方的發(fā)明者Isaac Eliaz博士說：這項研究是一個里程碑,，研究證明這一配方的安全性以及治療人前列腺癌動物模型的有效性,。這些積極成果為前列腺癌研究做出了重大貢獻(xiàn)，目前越來越多的數(shù)據(jù)證實天然化合物在治療前列腺癌中有作用,。
這一配方結(jié)合植物萃取物,、植物營養(yǎng)素、藥用真菌和抗氧化劑組成,。
Daniel Sliva說：多項研究已經(jīng)證明這種抑制前列腺癌的配方可能治療激素抵抗性（雄激素非依賴性）前列腺癌,。
研究發(fā)現(xiàn)與對照組相比，口服配方組的腫瘤生長被抑制了27％,。除了顯著減少腫瘤體積,，配方抑制促進(jìn)癌細(xì)胞擴(kuò)散和轉(zhuǎn)移的幾個基因（IGF2、NRNF2和PLAU/uPA）,。該配方也能增加抑癌基因CDKN1A的表達(dá),。
臨床前體內(nèi)研究的體外數(shù)據(jù)證實該配方能抑制激素抵抗性（雄激素非依賴性）人前列腺癌細(xì)胞PLAU/uPA基因的表達(dá)。（生物谷：Bioon.com)
doi:10.3892/ijo.2012.1344
PMC:
PMID:
ProstaCaid inhibits tumor growth in a xenograft model of human prostate cancer
Jiahua Jiang, Jagadish Loganathan, Isaac Eliaz, Colin Terry, George E. Sandusky, Daniel Sliva
We have recently demonstrated that the dietary supplement ProstaCaid(PC) inhibits growth and invasive behavior of PC-3 human prostate cancer cells in vitro. In the present study, we evaluated toxicity and whether PC suppresses growth of prostate cancer in a xenograft model of human prostate cancer cells implanted in mice. Here, we show that an oral administration of PC (100, 200 and 400 mg/kg) did not affect body weight or activity of liver enzymes (ALT, AST) and did not show any sign of toxicity in liver, spleen, kidney, lung and heart tissues in mice. In addition, PC treatment resulted in the inhibition of tumor volumes (1024.6±378.6 vs. 749.3±234.3, P<0.001) in a xenograft model of prostate cancer with human hormone refractory (independent) PC-3 prostate cancer cells. Moreover, qRT-PCR analysis demonstrated significant upregulation of expression of CDKN1A (p21) and inhibition of expression of IGF2, NR2F2 and PLAU (uPA) genes by an oral administration of PC in prostate cancer xenografts. Our study demonstrates that the concentrations of the dietary supplement ProstaCaid tested did not show signs of toxicity, and its oral application has significant anticancer activity in vivo and can be considered as an alternative treatment for prostate cancer patients.
